FGFR2 fusions might thus represent the most prevailing targetable alteration in CCA; however, the sensitivity of the different FGFR2 fusion proteins to specific FGFR2 inhibitors remains undefined and should be broadly investigated in future studies. This evidence concerns the gene FGFR2 and cholangiocarcinoma.